Guillain-Barre syndrome: background incidence rates in The Netherlands

被引:14
|
作者
van der Maas, Nicoline A. T. [1 ,2 ,3 ]
Kramer, Merlijn A. [1 ]
Jacobs, Bart C. [2 ,3 ]
van Soest, Eva M. [4 ]
Dieleman, Jeanne P. [4 ]
Kemmeren, Jeanet M. [1 ]
de Melker, Hester E. [1 ]
Sturkenboom, Miriam C. J. M. [5 ]
机构
[1] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands
[2] Univ Med Ctr, Dept Neurol, Rotterdam, Netherlands
[3] Univ Med Ctr, Dept Immunol, Rotterdam, Netherlands
[4] Univ Med Ctr, Dept Med Informat, Rotterdam, Netherlands
[5] Univ Med Ctr, Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands
关键词
Guillain-Barre syndrome; incidence rate; vaccination; PATIENT RECORDS; IMMUNIZATION; SURVEILLANCE; FEATURES;
D O I
10.1111/j.1529-8027.2011.00356.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Guillain-Barre syndrome (GBS) is a (sub) acute polyradiculoneuropathy, which may occur following immunization. To interpret the occurrence of GBS after introduction of large-scale immunization programmes, it is important to define recent background incidence rates (IRs) of GBS. We used a general practitioner electronic medical record database to assess age-specific GBS IRs between 1996 and 2008 in The Netherlands. All possible GBS cases were manually reviewed. Validated incident cases were reviewed by a neurologist (B. J.) for diagnostic certainty using the GBS case definition of the Brighton Collaboration (BC). In a population of 638,891 persons, we identified 23 validated incident GBS cases (mean age 46 years). IR was 1.14 per 100,000 person years (95% confidence interval [CI] 0.67-1.61) and was lower for people under 50 years (0.76; 95% CI 0.41-1.32) compared with elderly of 50 years or older (1.80; 95% CI 0.98-3.05). Only six cases fulfilled level 1 or 2 of diagnostic certainty of the BC case definition. IR of GBS increases with age. As vaccinations are often targeted at specific age groups, age-specific rates should be used to monitor GBS observed versus expected rates after introduction of large-scale vaccination programmes.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 50 条
  • [31] Pediatric Guillain-Barre syndrome
    Ryan, Monique M.
    CURRENT OPINION IN PEDIATRICS, 2013, 25 (06) : 689 - 693
  • [32] HyperCKemia in Guillain-Barre Syndrome
    Choi, Seok-Jin
    Hong, Yoon-Ho
    Kim, Jun-Soon
    Shin, Je-Young
    Sung, Jung-Joon
    EUROPEAN NEUROLOGY, 2020, 83 (04) : 415 - 420
  • [33] Guillain-Barre syndrome and pregnancy
    Boughammoura-Bouatay, A
    Hizem, Y
    Frih-Ayed, A
    REVUE DE MEDECINE INTERNE, 2005, 26 (04): : 325 - 326
  • [34] Guillain-Barre Syndrome and Vaccinations
    Salmon, Daniel A.
    Halsey, Neal A.
    CLINICAL INFECTIOUS DISEASES, 2013, 57 (02) : 205 - 207
  • [35] Update on Guillain-Barre syndrome
    Rinaldi, Simon
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2013, 18 (02) : 99 - 112
  • [36] Achalasia and Guillain-Barre Syndrome
    Mueller, M.
    Eckardt, V.
    Schrank, B.
    Graap, H.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2009, 47 (11): : 1149 - 1152
  • [37] GUILLAIN-BARRE SYNDROME IN CHILDHOOD
    Kollar Katalin
    Liptai Zoltan
    Rosdy Beata
    Moser Judit
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2009, 62 (11-12): : 399 - 404
  • [38] CHILDHOOD GUILLAIN-BARRE SYNDROME
    Barzegar, M.
    IRANIAN JOURNAL OF CHILD NEUROLOGY, 2009, 3 (01) : 7 - 14
  • [39] Immunotherapy of Guillain-Barre syndrome
    Liu, Shuang
    Dong, Chaoling
    Ubogu, Eroboghene Ekamereno
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (11) : 2568 - 2579
  • [40] Guillain-Barre syndrome: An update
    Vucic, Steve
    Kiernan, Matthew C.
    Cornblath, David R.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2009, 16 (06) : 733 - 741